Pipeline and research

Pipeline

Pre-ClinicalPhase IPhase IIPhase IIICommercialisation

Medi-Solfen® Human (Lacerations)

2025 phase II		Target 2027Target 2030

Medi-Solfen® Human (Leg Ulcers)

Q3 2026 phase II		Target 2028Target 2030

Medi-Solfen® Human (Post Op Pain Relief)

Phase I		Target 2028Target 2029Target 2030

Medi-Solfen® Human (Paediatric)*

Pre-Clinical		Target 2027Target 2028Target 2030Target 2031
In-house / available for partnering

* Studies as part of Paediatric Investigation Plan: Pre-Clinical

Medi-Solfen Pty Ltd has the commercial rights to 39+ patents in key global markets, with several new patents pending, providing protection until 2041.

See a full list of our patents, distribution partners and opportunities in our corporate profile document.

Download

Scientific papers & research

Recent scientific journals

  • International Wound Journal
    2019

    Innovative pain management solutions in animals may provide improved wound pain reduction during debridement in humans

    C. Roberts et al
  • Wounds UK
    2019

    Development of a UK cost analysis model for the various methods of debriding leg ulcers

    C. Roberts et al
  • Swansea University
    2018

    Determination of current standard care for management of patients with Venous Leg Ulcers

    College of Human & Health Sciences, Swansea University

USA Department of Defense

  • USDOD Peer Review
    2020

    A topical anaesthetic wound care agent to be used for frontline pain management of acute traumatic wounds

    The Summary Paper is available on request